TMS Co., Ltd. (JP:4891) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TMS Co., Ltd. has secured a U.S. patent for a new treatment for acute kidney injury using compounds including TMS-008, further strengthening its global intellectual property portfolio alongside recent grants in Japan and China. This development highlights TMS’s commitment to advancing innovative treatments in areas with high unmet medical needs.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.